FC26: Head-to-Head Insights on IL-17 Inhibitors in Psoriatic Disease: An Online Activity

Section cover
Releases on
November 30, 2026
Starts at
12:00am EST
Earn up to
0.5 AMA PRA Category 1 Credit(s)™

In this 20-minute Seminar in Depth, live from Fall Clinical 2026, Brad Glick, DO, MPH, and Mark Lebwohl, MD, examine the latest head-to-head evidence for IL-17 inhibitors in psoriatic disease. Join Drs. Glick and Lebwohl as they compare findings from key clinical trials and discuss how comparative efficacy and safety data can inform individualized biologic treatment selection for patients with psoriatic disease.

FC26: Head-to-Head Insights on IL-17 Inhibitors in Psoriatic Disease: An Online Activity

This activity is supported by an educational grant from UCB Inc.